The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Furthering cell therapy ambition across oncology and autoimmune diseases
Subscribe To Our Newsletter & Stay Updated
